14-3-3θ蛋白在乳腺癌中的表达和预后的临床研究

Expression and Prognosis of Clinical Study of 14-3-3θ Protein in Breast Cancer

目的:研究14-3-3夼蛋白在人乳腺癌中的表达和预后的临床意义。方法:在210例人乳腺癌组织样本中,通过免疫组化的方法检测14-3-3夼蛋白的表达情况,并分析其表达与乳腺癌临床病理学特征间的相关性及与患者总生存期的关系。结果:在210乳腺癌组织中,14-3-3夼蛋白的阳性表达为64.3%。卡方检验分析表明,14-3-3夼蛋白的表达与患者的发病年龄、肿瘤大小、组织分化程度以及HER2状态均没有相关性(P>0.05);而14-3-3夼蛋白高表达与高TNM分期(P=0.013)、淋巴结转移(P<0.0001)以及ER阴性(P=0.006)存在相关性。Spearman相关性分析检测发现,14-3-3夼蛋白高表达与高TNM分期(r=-0.187,P=0.006)、阳性淋巴结转移(r=-2.272,P<0.0001)呈正相关,而与ER阳性状态(r=-0.046,P=0.003)呈负相关。Kaplan-Meier分析结果显示:伴有14-3-3夼蛋白高表达患者的DFS与OS明显少于14-3-3夼蛋白低表达的患者,log-rank检验提示P值分别为0.0379和0.0037,具有统计学意义。结论:在乳腺癌组织中,14-3-3夼作为癌基因表达增加,与乳腺癌的发展和转移发生呈正相关,14-3-3夼可以作为乳腺癌患者预后和疾病复发的检测指标。

Objective： To investigate the expression and prognosis of clinical significances of 14-3-3θ protein in human breast cancer. Methods： Expression status of 14-3-3θ was detected by immunohistochemistry in 210 cases of human breast cancer specimens. Expressions, correlations and prognosis of 14-3-3θ were analyzed. Results： In 210 cases of breast cancer specimens, the positive expression of 14-3-3θ was 64.3%. The chi square test suggested that 14-3-3θ expression was not correlated with age, tumor size, histology, or HER2 status （P〉0.05）, while which was correlated with TNM stage, lymph node metastasis, and ER status （P〈0.05）. Correlation analysis suggested that 14-3-3θ expressions were positively correlated with advance TNM stage （r = -0.187, P = 0.006）, positive lymph node metastasis （r = -2.272, P 〈 0.0001）, and negative ER status （r = -0.046, P = 0.003）. Breast cancer patients with high 14-3-3θ expression had a shorter overall survival and a higher rate of recurrence than those with low 14-3-3θ expression （P = 0.0379 or 0.0037）. Conclusion： In breast cancer, expressions of 14-3-3θ increased and were correlated with tumor progression. 14-3-3θ may serve as a candidate prognostic biomarker in breast cancer progression.